Derangement of parathyroid function in renal failure: Biological and clinical aspects

Journal of Nephrology

Volumn 9, Issue 5, 1996, Pages 219-224

  Fukagawa, Masafumi ^a   Fukuda, Naoko ^a   Yi, Hung ^a   Kitaoka, Masafumi ^b   Kurokawa, Kiyoshi ^b,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b Kodaira shi   (Japan)

^c TOKAI UNIVERSITY   (Japan)

Author keywords

calcitriol; calcitriol receptor; parathyroid; parathyroid hormone; parathyroid hyperplasia; phosphate; renal failure

Indexed keywords

CALCITRIOL; CALCITRIOL RECEPTOR; PARATHYROID HORMONE;

HUMAN; KIDNEY FAILURE; PARATHYROID GLAND; PARATHYROID HYPERPLASIA; RENAL OSTEODYSTROPHY; REVIEW;

EID: 0029950375     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Malluche H, Faugere MC. Renal bone disease 1990: an unmet challenge for the nephrologist. Kidney Int 1990; 38: 193-211.
2. Coburn JW, Llach F. Renal osteodystrophy. In: Narins, ed. Clinical disorders of fluid and electrolyte metabolism, 5th ed. New York: McGrow Hill Book Co, 1994; 1299-377.
3. Akizawa T, Fukagawa M, Koshikawa S, Kurokawa K. Recent progress in management of secondary hyperparathyroidism of chronic renal failure. Current Opinion Nephrol Hypertens 1993; 2: 558-05.
4. Lindall AW, Elting J, Ellis J, Roos BA. Estimation of biologically active intact parathyroid hormone in normal and hyperparathyroid sera by sequential N-terminal immunoextraction and midregion radioimmunoassay. J Clin Endocrinol Metab 1983; 57: 1007-14.
5. Felsenfeld AJ, Llach F. Parathyroid function in chronic renal failure. Kidney Int 1993; 43: 771-89.
6. Slatopolsky EA, Weerts C, Thielan J, Horst R, Harter H, Martin KJ. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 1984; 74: 2136-43.
7. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989; 321: 274-9.
8. Tsukamoto Y, Nomura M, Takahashi Y, et al. The "Oral 1,25-dihydroxyvitamin D3 pulse therapy" in hemodialysis patients with severe secondary hyperparathyroidism. Nephron 1990; 56: 368-73.
9. Fukagawa M, Fukuda N, Yi H, Kurokawa K. Resistance to calcitriol as a cause of parathyroid hyperfunction in chronic renal failure. Nephrol Dial Trans 1995; 10: 316-9.
10. Fukagawa M, Kaname S, Igarashi T, Ogata E, Kurokawa K. Regulation of parathyroid hormone synthesis in chronic renal failure in rats. Kidney Int 1991; 39: 874-81.
11. Parfitt AM. Parathyroid growth: normal and abnormal. In: Bilezikian JP, Marcus R, Levine MA, eds. The parathyroid basic & clinical concepts. New York: Raven Press 1994; 373-406.
12. Fukagawa M, Okazaki R, Takano K, et al. Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis. N Engl J Med 1990; 323: 421-2.
13. Quarles LD, Yohay DA, Carroll BA, et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyper-parathyroidism in ESRD. Kidney Int 1994; 45: 1710-21.
14. Hyodo T, Koumi T, Ueda M, et al. Can oral 1,25(OH)2D3 therapy reduce parathyroid hyperplasia? Nephron 1991; 59: 171-2.
15. Cannella G, Bonucci E, Rolla D, et al. Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol. Kidney Int 1994; 46: 1124-32.
16. Reichel H, Szabo A, Uhl J, et al. Intermittent versus continuous administration of 1,25-dihydroxyvitamin D3 in experimental renal hyperparathyroidism. Kidney Int 1993; 44: 1259-65.
17. Fukagawa M, Kitaoka M, Yi H, et al. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients: Nephron 1994; 68: 221-8.
18. Akerstrom G, Malmaeus J, Grimelius L, Liunghall S, Bergstrom R. Histological changes in parathyroid glands in subclinical and clinical renal disease. Scand J Urol Nephrol 1984; 18: 75-84.
19. Tominaga Y, Grimelius L, Falkmer UG, Johannson H, Falkmer S. DNA ploidy pattern of parathyroid parenchyman cells in renal secondary hyperparathyroidism with relapse. Analyt Cell Pathol 1991; 3: 325-33.
20. Tominaga Y, Tanaka Y, Sato K, et al. Recurrent renal hyperparathyroidism and DNA analysis of autografted parathyroid tissue. World J Surg 1992; 16: 595-603.
21. Tominaga Y, Takagi H. Molecular genetics of hyperparathyroid disease. Current Opinion Nephrol Hypertens 1996 (in press).
22. Fukagawa M, Kitaoka M, Fukuda N, Yi H, Kurokawa K. Pathogenesis and management of parathyroid hyperplasia in chronic renal failure: role of calcitriol. Mineral Elect Metab 1995; 21: 97-100.
23. 3H] 1,25-dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure. N Engl J Med 1987; 316: 1573-7.
24. Merke J, Hugel U, Zlotowski A, et al. Diminished parathyroid 1,25(OH)2D3 receptors in experimental uremia. Kidney Int 1987; 32: 350-3.
25. Brown A, Dusso A, Lopez-Hilker S, Lewis-Finch J, Grooms P, Slatopolsky EA. 1,25(OH)2D receptors are decreased in parathyroid glands from chronically uremic dogs. Kidney Int 1989; 35: 19-23.
26. Malmaeus J, Glimelius L, Johansson G, Akerstrom G, Ljunghall S. Parathyroid pathology in hyperparathyroidism secondary to chronic renal failure. Scand J Urol Nephrol 1984; 18: 157-66.
27. Tominaga Y, Takagi H, Suzuki H, Kondo T. Histopathological study of parathyroid gland in renal hyperparathyroidism. J Jpn Surg Soc 1985; 86: 630-9.
28. Wallfelt CH, Larsson R, Gylfe E, Ljunghall S, Rasted J. Akerstrom. Secretory disturbance in hyperplastic parathyroid nodules of uremic hyperparathyroidism: implication for parathyroid autoplantation. World J Surg 1988; 12: 431-8.
29. Tominaga Y, Sato K, Tanaka Y, Numano M, Uchida K, Takagi H. Histopathology and pathophysiology of secondary hyperparathyroidism due to chronic renal failure. Clin Nephrol 1995; 44: S42-7.
30. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993; 92: 1436-43.
31. Naveh-Many T, Marx R, Keshet E, Pike JW, Silver J. Regulation of 1,25-dihydroxyvitamin D3 receptor gene expression by 1,25-dihydroxyvitamin D3 in the parathyroid in vivo. J Clin Invest 1990; 86: 1968-75.
32. Koyama H, Nishizawa Y, Inaba M, et al. Impaired homologous upregulation of vitamin D receptor in rats with chronic renal failure. Am J Physiol 1994; 266: F706-12.
33. Patel SR, Ke HQ, Hsu CH. Regulation of calcitriol receptor and its mRNA in normal and renal failure rats. Kidney Int 1994; 45: 1020-7.
34. Hsu CH, Patel SR, Young EW, Vanholder R. The biological action of calcitriol in renal failure. Kidney Int 1994; 46: 605-12.
35. Shvil Y, Naveh-Many T, Brach P, Silver J. Regulation of parathyroid cell gene expression in experimental uremia. J Am Soc Nephrol 1990; 1: 99-104.
36. Patel SR, Ke H-Q, Vanholder R, Koenig RJ, Hsu CH. Inhibition of calcitriol receptor binding to vitamin D responsive elements by uremic toxins. J Clin Invest 1995; 96: 50-9.
37. Lopez-Hilker S, Dusso AS, Rapp NS, Martin KJ, Slatopolsky E. Phosphorus restriction reverses secondary hyperparathyroidism independent of changes in calcium and calcitriol. Am J Physiol 1990; 259: F432-7.
38. Yi H, Fukagawa M, Yamato H, Kumagai M, Watanabe T, Kurokawa K. Prevention of enhanced parathyroid hormone secretion, synthesis and hyperplasia by mild dietary phosphorus restriction in early chronic renal failure in rats: possible direct role of phosphorus. Nephron 1995; 70: 242-8.
39. Kilaf R, Silver J, Naveh-Many T. Parathyroid hormone gene expression in hypophosphatemic rats. J Clin Invest 1995; 96: 232-33.
40. Denda M, Finch J, Slatopolsky. Phosphorus restriction prevents the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure (abstract). J Am Soc Nephrol 1995; 6: 959.
41. Naveh-Many T, Rachmimov R, Livni N, Silver J. Parathyroid cell proliferation in normal and chronic renal failure rats. J Clin Invest 1995; 96: 1786-93.
42. Almaden Y, Hernandez A, Torregrosa V, Campistol J, Torres A, Rodriguez M. High phosphorus directly stimulates PTH secretion by human parathyroid tissue (abstract). J Am Soc Nephrol 1995; 6: 957.
43. 4) restriction prevents parathyroid cell growth in uremic rats and high phosphate directly stimulates PTH secretion in tissue culture (abstract). J Am Soc Nephrol 1995; 6: 971.
44. Iida K, Shinki T, Yamaguchi A, De Luca HF, Kurokawa K, Suda T. A possible role of vitamin D receptors in regulating vitamin D activation in the kidney. Proc Natl Acad Sci USA 1995; 92: 6112-6.
45. Portale AA, Halloran BP, Murphy MM, Morris Jr RC. Oral intake of phosphorus can determine the serum concentration of 1,25-dihydroxyvitamin D by determining its production rate in humans. J Clin Invest 1986; 77: 7-12.
46. Russell J, Bar A, Sherwood LM, Hurwitz S. Interaction between calcium and 1,25-dihydroxyvitamin D3 in the regulation of preproparathyroid hormone and vitamin D receptor messenger ribonucleic acid in avian parathyroids. Endocrinol 1993; 132: 2639-44.
47. Sriussadaporn S, Wong MS, Pike JW, Favus MJ. Tissue specificity and mechanism of vitamin D receptor up-regulation during dietary phosphorus restriction in the rat. J Bone Miner Res 1995; 10: 271-80.
48. Arnold A, Brown MF, Urena P, Gaz RD, Sarfati E, Drueke TB. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 1995; 95: 2047-53.
49. Falchetti A, Bale AE, Amorosi A, et al. Progression of uremic hyperparathyroidsm involves alleic loss on chromosome 11. J Clin Endocrinol Metab 1993; 76: 139-44.
50. Tominaga Y, Kohara S, Namii Y, et al. Clonal analysis of nodular hyperplasia in renal hyperparathyroidism. World J Surg (in press).
51. Druecke TB. The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Kidney Int 1995; 48: 259-72.
52. Arnold A. Genetic basis of endocrine disease 5: molecular genetics of parathyroid gland neoplasia. J Clin Endocrinol Metab 1993; 77: 1108-12.
53. Solbiati L, Giangrande A, Pra LD, Bellotti E, Cantu P, Ravetto C. Ultrasound-guided percutaneous fine-needle ethanol injection into parathyroid glands in secondary hyperparathyroidism. Radiology 1985; 155: 607-10.
54. Giangrande A, Castiglioni A, Solbiati L, Allaria P. Ultrasound guided percutaneous fine needle ethanol injection into parathyroid glands in secondary hyperparathyroisism. Nephrol Dial Transplant 1992; 7: 412-21.
55. Kitaoka M, Fukagawa M, Ogata E, Kurokawa K. Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients. Kidney Int 1994; 46: 1110-7.
56. Fukagawa M, Kitaoka M, Kurokawa K. Ultrasonographic intervention of parathyroid hyperplasia in chronic dialysis patients: a theoretical approach. Nephrol Dial Trans (in press).
57. Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992; 75: 145-50.
58. Sherrard DJ, Herez G, Pei Y, Chan W, Maloney N. Parathyroid hormone (PTH): goal value to prevent symptomatic renal osteodystrophy (ROD) (abstract). J Am Soc Nephrol 1994; 5: 888.
59. Hercz G, Pei Y, Greenwood C, et al. Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function. Kidney Int 1993; 44: 860-6.
60. Goodman WG, Ramirez JA, Belin TR, et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994; 1160-6.
61. Kitaoka M, Fukagawa M, Kurokawa K. Direct injection of calcitriol into parathyroid hyperplasia in chronic dialysis patients with severe parathyroid hyperfunction. Nephrology 1995; 1: 563-8.
62. Fukuda N, Katoh T, Yi H, et al. Successful in vivo gene transfer into parathyroid glands with adenoviral vector delivered by selective injection in rats (abstract). J Am Soc Nephrol 1995; 6: 961.
63. Goodman WG, Coburn JW. The use of 1,25-dihydroxyvitamin D3 in early renal failure. Annu Rev Med 1992; 43: 227-37.